tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

KNSA Stock Latest News

Kiniksa Pharmaceuticals Q1 2025 Earnings: Strong Growth
Company AnnouncementsKiniksa Pharmaceuticals Q1 2025 Earnings: Strong Growth
5d ago
KNSA
Kiniksa announces Carly Pearce joined the Life DisRPted Campaign
PremiumThe Fly
Kiniksa announces Carly Pearce joined the Life DisRPted Campaign
6d ago
KNSA
Kiniksa Pharmaceuticals Reports Strong Q1 2025 Growth
PremiumCompany Announcements
Kiniksa Pharmaceuticals Reports Strong Q1 2025 Growth
6d ago
KNSA
Kiniksa price target raised to $45 from $40 at Jefferies
PremiumThe Fly
Kiniksa price target raised to $45 from $40 at Jefferies
7d ago
KNSA
Kiniksa reports Q1 EPS 11c, consensus 28c
PremiumThe Fly
Kiniksa reports Q1 EPS 11c, consensus 28c
7d ago
KNSA
Kiniksa sees FY25 ARCALYST net product revenue $590M-$605M
PremiumThe FlyKiniksa sees FY25 ARCALYST net product revenue $590M-$605M
7d ago
KNSA
Kiniksa Pharmaceuticals Approves Long-Term Incentive Plan
Premium
Company Announcements
Kiniksa Pharmaceuticals Approves Long-Term Incentive Plan
13d ago
8K
KNSA
Kiniksa initiated with a Buy at Citi
Premium
The Fly
Kiniksa initiated with a Buy at Citi
2M ago
KNSA
Kiniksa Pharmaceuticals Reports Strong Growth Amid Challenges
PremiumCompany Announcements
Kiniksa Pharmaceuticals Reports Strong Growth Amid Challenges
2M ago
KNSA
Kiniksa price target lowered to $30 from $35 at Wells Fargo
PremiumThe Fly
Kiniksa price target lowered to $30 from $35 at Wells Fargo
2M ago
KNSA
Buy Rating for Kiniksa Pharmaceuticals Driven by Strategic Refocus and Commercial Success
PremiumRatings
Buy Rating for Kiniksa Pharmaceuticals Driven by Strategic Refocus and Commercial Success
2M ago
KNSA
Kiniksa Pharmaceuticals: Strategic Focus on Cardiovascular Growth and Stability Underpins Buy Rating
PremiumRatings
Kiniksa Pharmaceuticals: Strategic Focus on Cardiovascular Growth and Stability Underpins Buy Rating
2M ago
KNSA
Kiniksa Pharmaceuticals Reports Strong ARCALYST Growth
PremiumCompany AnnouncementsKiniksa Pharmaceuticals Reports Strong ARCALYST Growth
2M ago
KNSA
Kiniksa Pharmaceuticals Ends License Agreement with MedImmune
Premium
Company Announcements
Kiniksa Pharmaceuticals Ends License Agreement with MedImmune
2M ago
8K
KNSA
Kiniksa reports Q4 EPS (12c), consensus 13c
Premium
The Fly
Kiniksa reports Q4 EPS (12c), consensus 13c
2M ago
KNSA
Kiniksa sees FY25 ARCALYST net product revenue $560M-$580M
PremiumThe Fly
Kiniksa sees FY25 ARCALYST net product revenue $560M-$580M
2M ago
KNSA
Kiniksa announces development of KPL-387, updated corporate strategy
PremiumThe Fly
Kiniksa announces development of KPL-387, updated corporate strategy
2M ago
KNSA
Kiniksa to discontinue development of abiprubart in Sjogren’s Disease
PremiumThe Fly
Kiniksa to discontinue development of abiprubart in Sjogren’s Disease
2M ago
KNSA
Kiniksa Pharmaceuticals Ltd. Class A (KNSA) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Kiniksa Pharmaceuticals Ltd. Class A (KNSA) Q4 Earnings Cheat Sheet
2M ago
KNSA
Kiniksa reports preliminary Q4 ARCALYST net product revenue $121.9M
PremiumThe FlyKiniksa reports preliminary Q4 ARCALYST net product revenue $121.9M
4M ago
KNSA
Short Report: CompoSecure shorts at multi-month lows
Premium
The Fly
Short Report: CompoSecure shorts at multi-month lows
4M ago
IEP
CMPO
Kiniksa Pharmaceuticals (KNSA) Stock Drops 17%, Presenting a Potential Opportunity
Premium
Market News
Kiniksa Pharmaceuticals (KNSA) Stock Drops 17%, Presenting a Potential Opportunity
6M ago
KNSA

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >